Epizyme (EPZM) : 6 brokerage houses believe that Epizyme (EPZM) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 7 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.14.
Epizyme (EPZM) : The consensus price target for Epizyme (EPZM) is $25.17 for the short term with a standard deviation of $7.36. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $39, however, the pessimist price target for the company is $18.
Epizyme (NASDAQ:EPZM): After opening at $8.16, the stock dipped to an intraday low of $8.16 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.98 and the buying power remained strong till the end. The stock closed at $8.89 for the day, a gain of 9.21% for the day session. The total traded volume was 711,978. The stocks close on the previous trading day was $8.14.
Epizyme, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Companys product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. The Companys lead product candidate, EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling, and Phase I MLL-r pediatric patient trial enrolling.